Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice.

Even Fjære, Ulrike L Aune, Kristin Røen, Alison H Keenan, Tao Ma, Kamil Borkowski, David M Kristensen, Guy W Novotny, Thomas Mandrup-Poulsen, Brian D Hudson, et al.

To cite this version:

Even Fjære, Ulrike L Aune, Kristin Røen, Alison H Keenan, Tao Ma, et al.. Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice.. Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, 2014, 289 (23), pp.16032-45. <10.1074/jbc.M113.525220>. <hal-01074835>
Cyclooxygenase inhibition and regulation of glucose homeostasis

Indomethacin treatment prevents high-fat diet-induced obesity and insulin resistance, but not glucose intolerance in C57BL/6J mice

Even Fjære1,2, Ulrike L. Aune1,2, Kristin Røen1, Alison H. Keenan1,3, Tao Ma1, Kamil Borkowsky1, David M. Kristensen5,6, Guy W. Novotny7, Thomas Mandraup-Poulsen7,8, Brian D. Hudson9, Graeme Milligan9, Yannan Xi3, John W. Newman3,10, Fawaz G. Haj1,4, Bjørn Liaset2, Karsten Kristiansen1,4, and Lise Madsen1,2,*

1Department of Biology, University of Copenhagen, Copenhagen, Denmark. 2National Institute of Nutrition and Seafood Research, Bergen, Norway. 3Department of Nutrition and 4Internal Medicine, University of California, Davis, USA. 5Institut National de la Santé et de la Recherche Médicale (INSERM) U1085-IRSET, Université de Rennes 1, Rennes, France. 6Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. 7Section for Endocrinological Research, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. 8Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden. 9Institute of Molecular, Cell and Systems Biology, University of Glasgow, Scotland, United Kingdom. 10USDA/ARS Western Human Nutrition Research Center, California, USA.

Running title: Cyclooxygenase inhibition and regulation of glucose homeostasis.

* Correspondence to: Lise Madsen, National Institute of Nutrition and Seafood Research, P.O. BOX 2029 Nordnes, N-5817 Bergen, Norway. Fax: +47 5590 5299; Phone: +47 4147 6177; Email: lise.madsen@nifes.no or Karsten Kristiansen, Department of Biology, University of Copenhagen, Ole Maaløes Vej 5, DK-2200 Copenhagen N, Denmark. Fax: +45 3532 2128; Phone: +45 3532 4443; Email: kk@bio.ku.dk

Keywords: Adipose tissue; Cyclooxygenases (COXs) pathway; Cyclooxygenase inhibitors; G-protein coupled receptor; Glucose intolerance; Insulin resistance; Insulin secretion

Background: Obesity-associated insulin resistance is linked to inflammation.

Results: Indomethacin, an anti-inflammatory cyclooxygenase inhibitor, prevented diet-induced obesity and overall peripheral insulin resistance, but mice became glucose intolerant with sustained hepatic glucose output. Selective activation of the fatty acid receptor GPR40 in the presence of indomethacin impaired glucose-stimulated insulin secretion, in part explaining the interaction between intake of a high fat obesogenic diet and indomethacin.

Conclusion: Inhibition of cyclooxygenase activity alters the metabolic consequences of an obesogenic diet.

Significance: Intake of anti-inflammatory cyclooxygenase inhibitors may impair glucose tolerance.

ABSTRACT
Chronic low-grade inflammation is closely linked to obesity-associated insulin resistance. To examine how administration of the anti-inflammatory compound indomethacin, a general cyclooxygenase inhibitor, affected obesity development and insulin sensitivity, we fed obesity-prone male C57BL/6J mice a high fat/high sucrose (HF/HS) diet or a regular diet supplemented or not with indomethacin (+/-INDO) for 7 weeks. Development of obesity, insulin resistance and glucose tolerance was monitored, and the effect of indomethacin on glucose stimulated insulin-secretion (GSIS) was measured in vivo, and in vitro using MIN6 ß-cells. We found that supplementation with indomethacin prevented HF/HS-induced obesity and diet-induced changes in systemic insulin sensitivity. Thus, HF/HS+INDO fed mice
remained insulin sensitive. However, mice fed HF/HS+INDO, exhibited pronounced glucose intolerance. Hepatic glucose output was significantly increased. Indomethacin had no effect on adipose tissue mass, glucose tolerance or GSIS when included in a regular diet. Indomethacin administration to obese mice did not reduce adipose tissue mass, and the compensatory increase in GSIS observed in obese mice was not affected by treatment with indomethacin. We demonstrate that indomethacin did not inhibit GSIS per se, but activation of GPR40 in the presence of indomethacin inhibited glucose-dependent insulin secretion in MIN6 cells. We conclude that constitutive high hepatic glucose output combined with impaired GSIS in response to activation of GPR40-dependent signaling in the HF/HS+INDO fed mice contributed to the impaired glucose clearance during a glucose challenge, and that the resulting lower levels of plasma insulin prevented the obesogenic action of the HF/HIS diet.

INTRODUCTION

Chronic low-grade inflammation is a key factor underlying obesity-associated insulin resistance (1,2). Cyclooxygenase (COX) derived prostaglandins (PGs) are mediators of tissue inflammation, but may also influence insulin secretion as well as adipocyte differentiation and function. The relationship between PGs and insulin secretion is complex and apparently conflicting results have been reported. Increased levels of PGs have been associated with impaired β-cell function (3). PGE₂ was reported to reduce glucose-stimulated insulin secretion (GSIS), and accordingly, administration of COX inhibitors increased GSIS and improved glucose disposal (4). By contrast, administration of the general COX inhibitor, indomethacin, a commonly used nonsteroidal anti-inflammatory drug (NSAID), has been shown to decrease insulin secretion in T2DM patients (5), and to lower glucose-stimulated acute insulin response (6).

PGs have both pro- and anti-obesogenic properties (7). Others and we have shown that both diet- and cold-induced appearance of brown-like adipocytes, termed “bricate” or “beige” adipocytes in white adipose tissues requires COX expression and activity (8,9).

Thus, in the apparently obesity-resistant Sv129 mouse strain, treatment with indomethacin, attenuated diet-induced expression of uncoupling protein 1 (Ucp1) in inguinal white adipose tissue (iWAT), thereby promoting the development of diet-induced obesity (8).

The present study was designed to examine how indomethacin affected diet-induced obesity and the associated metabolic disorders in obesity prone male C57BL/6J mice. In sharp contrast to the effect in Sv129 mice (8), indomethacin treatment prevented the obesogenic effects of a high fat/high sucrose (HF/HS) diet in C57BL/6J mice. Our results reveal an interesting and complex phenotype of HF/HIS fed C57BL/6J mice treated with indomethacin (HF/HIS+INDO). Compared with C57BL/6J mice fed a HF/HIS diet, mice fed a HF/HIS+INDO diet were lean and remained insulin sensitive, yet they became glucose intolerant; a feature likely associated with impaired regulation of hepatic gluconeogenesis and impaired compensatory upregulation of pancreatic insulin secretion.

EXPERIMENTAL PROCEDURES

Mouse care and maintenance. Eight week old male C57BL/6JbomTac mice (Taconic, Fjby, Denmark) were acclimatized for 1 week under thermoneutral conditions (28-30°C) with a 12-hour light and dark cycle. Mice were housed individually. Two sets of mice were assigned to three groups (n=9/group) and fed a low fat (LF), regular diet (RD) (ssniff EF R/M Control, Germany), a HF/HIS diet, (ssniff S8672-E056 EF, Germany) or a HF/HIS diet supplemented with indomethacin (16 mg/kg) (Sigma-Aldrich, Norway) for 7 weeks. A third set of mice were fed a HF/HIS diet for 10 weeks before they were fed the HF/HIS diet supplemented with indomethacin. A fourth set of mice was given saline or indomethacin (2.5 mg/kg body mass), dissolved in saline, by gavage after 5 hours fasting and 1 hour prior to glucose administration. In all experiments, food intake was recorded three times a week, and body weight once per week. All animal experiments were approved by the National State Board of Biological Experiments with Living Animals (Norway and Denmark).

Glucose, insulin and pyruvate tolerance test. For glucose tolerance test (GTT) and pyruvate
tolerance test (PTT) the animals were injected i.p. after 6 hours of fasting with 2 g glucose/kg body weight or 2 g sodium pyruvate (Sigma-Aldrich)/kg body weight (10). For insulin tolerance test (ITT) 0.75 U human insulin (Actrapid, Denmark)/kg body weight was injected i.p. in the fed state. For all tests, blood was collected from the tail vein of conscious animals and blood glucose was measured using a glucometer (Ascensia Contour, Bayer, Norway) at baseline and at the indicated times.

Glucose-stimulated insulin secretion. Mice fasted for 3 hours were injected i.p. with 3 g glucose/kg body weight. Blood (30μl) was collected from the tail vein at baseline and 2, 5 and 10 minutes after glucose injection.

Indirect calorimetry. After 6 weeks on their respective diets and a 24 hour acclimatization period, O2 and CO2 gas exchange measurements were obtained for a 24 hour period from each mouse, using the open circuit chambers of the Labmaster system (TSE Systems GmbH, Germany) (11).

Termination and tissue harvest. Mice were anesthetized with isoflurane (Isoba-vet, Schering-Plough, Denmark) and euthanized by cardiac puncture. Blood samples were collected in tubes containing EDTA anticoagulant. Organs were immediately dissected, weighed, and flash-frozen in liquid nitrogen and stored at -80°C.

Histology examinations. Paraffin embedded sections of eWAT and iWAT were stained with haematoxylin and cosin, and analyzed as previously described (12). Sections of pancreatic tissue were stained for insulin, and pancreatic islet and section sizes were analyzed (13). Immunohistological detection of UCP1 positive multilocular cells was performed by an avidin-biotin peroxidase method. After deparaffinification and rehydration, 5 μm sections were processed through citrate buffer (pH6), 2x15 min (95°C). Sections were transferred to 0.3% hydrogen peroxide in methanol (30 min), before incubation with 10% goat serum (30 min), and incubation with primary antibody 1:4000 in PBS (goat serum 1%) overnight (4°C). Secondary antibody 1:200 was applied for 1 hour and incubation with the ABC complex (Vectastain ABC kit, Vector Laboratories), as described by the manufacturer. DAB (3,3'-diaminobenzidine) (Vector Laboratories, Burlingame, CA) substrate kit was applied, before counterstaining with hematoxylin and mounting. F4/80 immunohistological detection of macrophages in adipose tissue was performed by using the F4/80 sc-52664 (BM8) antibody and ImmunoCris rat ABC staining system sc-2019 as described by the manufacturer (Santa Cruc Biotechnology, Texas, USA).

Cell culture. MIN6 cells were cultured at 37°C in a humified atmosphere containing 5% CO2 in RPMI1640 media with GlutaMAX supplemented with 10% [vol./vol.] FCS, 100 U/ml penicillin, 100 μg/ml streptomycin (all from Invitrogen/Gibco, Denmark) and 50 μmol/l β-mercaptoethanol (Sigma) together with vehicle (DMSO) or 1μM indomethacin. After 48 hours, cells were washed and incubated for 30 min in Krebs-Ringer-bicarbonate buffer (KRB) containing 135 mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4, 2 mM NaHCO3, 0.5 mM MgCl2, 1.5 mM CaCl2, 10 mM HEPES, 2.8 mM glucose and 0.05% BSA, together with either indomethacin or vehicle. The buffer was replaced with 0.5 ml fresh KRB containing either vehicle, indomethacin, 10 μM TUG469, a synthetic GPR40 agonist (14) or a combination. Insulin release was measured after 1 hour.

MIN6 viability measurements over 48 hours were performed using the xCELLigence platform (Roche Diagnostics) (15), with indomethacin or vehicle (DMSO) added after 24 hours of growth.

Bioluminescence Resonance Energy Transfer (BRET) based β-arrestin-2 interaction assay. HEK293T cells were transiently transfected using polyethylenimine with constructs encoding mouse GPR40 tagged at its carboxy terminal with enhanced yellow fluorescence protein and β-arrestin-2 fused with Renilla luciferase. The ability of TUG469 and indomethacin to affect interaction between the mouse GPR40 and β-arrestin-2 constructs was assessed using the BRET based method (16). The resulting concentration-response data were fit to 3-parameter sigmoid curves using
GraphPad Prism v 5.0 (GraphPad Software, Inc., San Diego, CA, USA).

**Plasma measurements.** Glycerol, NEFA, plasma glucose, alanine aminotransferase (ALT) and aspartate transaminase (AST) concentrations in plasma were analyzed with commercially available enzymatic kits (DiaLab, Vienna, Austria) using an autoanalyzer (MaxMat SA, Montpellier, France). Insulin Mouse Ultrasensitive ELISA kit (DRG Diagnostics GmbH, Germany) was used for quantitative determination of insulin in plasma. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated from fasting insulin and glucose concentrations using the formula: plasma glucose (mmol/l)/fasting insulin (μU/ml) + 22.5 (17). QUICKI was calculated using the formula: 1/(log(fasting insulin μU/ml) + log(fasting glucose mg/dl)) (18).

**Real time RT-qPCR.** RNA was extracted from tissue, cDNA synthesized and gene expression measured as described (19).

**Tissue lipid extraction and lipid class analysis.** Total lipid was extracted from liver and muscle samples with chloroform:methanol, 2:1 (v/v) and quantified on a Camaq High performance thin layer chromatography (HPTLC) system and separated on HPTLC silica gel (20). Total lipid was extracted from feces and quantified in samples from 48 hours collection (12) after 6 weeks of treatment with the respective diets.

**Plasma oxyxilipins.** Plasma samples were extracted using Oasis HLB solid phase extraction cartridges (Waters Corp Inc, Milford MA, USA) as previously described (21). Analytes were eluted with methanol and ethyl acetate into 6μl glycerol, subjected to vacuum evaporation, and the resulting glycerol plug was stored at -80°C. Prior to analysis, samples were reconstituted in methanol containing 100nM of each internal standard 1-cyclohexylureido-3-dodecanoic acid and 1-phenylurea-3-hexanoic acid (Sigma-Aldrich), followed by filtration at 0.1μm and analysis by UPLC-MS/MS. The analytes were separated using a reverse phase solvent gradient on a 2.1 x 150mm, 1.7μm Acquity BEH column, ionized by negative mode electrospray ionization and detected by multi-reaction monitoring mode on an ABI 4000QTRAP (ABSciex, Foster City, CA, USA) triple quadrupole mass spectrometer (22).

**Statistics.** All results are shown as mean ± SEM unless otherwise indicated. Statistical analyses of physiological and gene expression data were performed with GraphPad Prism v 5.0 (GraphPad Software, Inc.), and Dixon’s Q-test was used to screen for outliers. One-way ANOVA was used to compare differences between the experimental groups, followed by Fisher’s LSD test unless otherwise indicated. A significance level of P<0.05 was used for all tests. Statistical significances are denoted with stars; * P<0.05, ** P<0.01, *** P<0.001.

**RESULTS**

**Indomethacin prevents diet-induced obesity in C57BL/6J mice.** Obesity-prone C57BL/6J mice were fed a HF/HS diet with or without indomethacin. Mice fed a HF/HS diet had increased weight gain, increased white adipose tissue (WAT) and liver masses compared with mice fed RD, whereas these increases were prevented in mice fed HF/HS+INDO (Fig. 1A, B, C and D). No differences in weights of iBAT (Fig. 1E) or of the skeletal muscles, tibialis anterior or soleus were observed (data not shown).

**Indomethacin reduces feed efficiency.** To confirm that the reduced obesity in HF/HS+INDO fed mice was not simply due to reduced energy intake, feed intake was monitored. Energy intake was comparable between HF/HS and HF/HS+INDO fed mice (Fig. 1F), and thus, indomethacin supplementation reduced feed efficiency (Fig. 1G). As indomethacin has been reported to decrease bile acid secretion, with a possible effect on fat absorption (23,24), the apparent fat digestibility was calculated. Indomethacin treatment did not decrease fat absorption compared with mice fed the HF/HS diet, but both HF/HS fed groups had increased fat absorption compared to RD fed mice (Fig. 1H).

The reduced feed efficiency and higher percentage weight loss after 12 hours starvation (Fig. 1I) in HF/HS+INDO fed mice compared with HF/HS fed mice could indicate increased metabolic activity and therefore
indirect calorimetry measurements were performed. O₂ consumption, CO₂ production and the respiratory exchange ratio (RER) were similar in the HF/HS and HF/HS+INDO fed groups. No significant difference was observed between HF/HS and HF/HS+INDO, but O₂ consumption, CO₂ production and the respiratory exchange ratio (RER) were significantly lower compared to the RD fed mice (Fig. 2A-C). Unexpectedly, expression of Ucp1 in iWAT was higher in mice fed HF/HS+INDO than in mice fed HF/HS, but comparable in their iBAT and eWAT (Fig. 2D). Expression of other brown adipocyte markers was not significantly different (Fig. 2E and F). To evaluate if the increased mRNA expression of Ucp1 in iWAT was accompanied with UCP1 positive multilocular cells, immunohistochemical (IHC) analyses of both eWAT and iWAT were performed. The IHC staining revealed no induction of UCP1 positive cells in eWAT, irrespective of diet group, however, in agreement with the mRNA levels of Ucp1 a minute induction was observed in iWAT of mice fed HF/HS+INDO (Fig. 2G). Despite a significant induction of Ucp1 within iWAT, the relative expression is extremely low compared the expression seen in iWAT of obesity-resistant mouse strains. Thus, we conclude that the low level of UCP1 in iWAT in mice fed the HF/HS+INDO diet is insufficient to explain energy balance and the observed differences in body weight and fat mass.

**Indomethacin increases plasma glycerol and NEFA in the fasted state.** The reduced feed efficiency in HF/HS+INDO compared with HF/HS fed mice was not associated with increased plasma levels of AST or ALT. (Fig. 2H), indicating that the low dose of indomethacin in the diet did not cause liver injury (Fig. 2H). PGs, PGE₂ in particular, inhibit lipolysis (25). Hence, we asked if treatment with indomethacin would affect lipolysis. In the fed state, glycerol and NEFA levels were comparable in all groups (Fig. 2I and J). However, in the fasted state, both glycerol and NEFA levels were higher in HF/HS+INDO than in HF/HS fed mice (Fig. 2I and J), indicating increased mobilization of fat from adipose tissue in indomethacin treated mice. This effect might reflect a more unabated ability of the increased levels of cAMP to increase lipolysis during fasting in the absence of inhibitory PGE₂.

**Indomethacin prevents diet-induced hypertrophy and attenuates expression of inflammatory markers in iWAT.** As hypertrophy is associated with increased infiltration of macrophages and low grade inflammation (26), histological examinations and gene expression analyses of macrophage infiltration markers were performed. HF/HS diet-induced hypertrophy of eWAT and iWAT was prevented by indomethacin treatment (Fig. 3A). Expression of markers for macrophage infiltration and inflammation in eWAT was not increased significantly in response to HF/HS feeding for 7 weeks, except for Chemokine ligand 2 (Ccl2) (Fig. 3B-E). On the other hand, expression of Cd68, and Ccl2 in iWAT was significantly reduced by an HF/HS diet with indomethacin supplementation. Expression of Emr1 (P = 0.08) also tended to be reduced in HF/HS+INDO fed mice (Fig. 3F-I).

Macrophage infiltration in AT depots was evaluated by IHC staining with F4/80 antibody. The evaluation of F4/80 positive macrophages showed infiltration in the AT of mice given LF, HF/HS and HF/HS+INDO, and is in agreement with the mRNA expression. Despite no significant differences in the number of F4/80 positive macrophages per 100 counted adipocytes (eWAT: RD = 43.9 ± 6.2, HF/HS= 58.7 ± 5.0 and HF/HS+INDO = 50.1 ± 6.8, and iWAT: RD = 31.1±6.5, HF/HS = 34.4±4.8 and HF/HS+INDO = 27.7±2.4), IHC revealed that the formation of crown-like structures (CLSs) was only observed in the HF/IIS-diet group (Fig. 3J).

**Plasma oxylipin profiles in mice fed HF/HS and HF/HS+INDO.** To ascertain the efficacy of indomethacin treatment and obtain an overview of changes in plasma eicosanoids, plasma non-esterified oxylipin profiles were assessed. Cyclooxygenase-dependent metabolite levels in plasma were significantly reduced in mice given HF/HS+INDO compared with mice given a HF/HS diet. The levels of prostaglandins 6-keto PGF₁₅, PGD₂ as well as thromboxane B₂ (TXB₂) were significantly reduced by indomethacin supplementation, suggesting impacts on both
COX1 and COX2 dependent metabolism (Table 1).

*Indomethacin supplementation attenuates HF/HS-induced diacylglycerol and triacylglycerol accumulation in liver and skeletal muscle.* To investigate if the reduced adipose tissue mass in HF/HS+INDO fed mice was associated with increased ectopic fat accumulation, different lipid classes were quantified in liver and muscle tissue. Indomethacin attenuated HF/HS-induced accumulation of triacylglycerol (TAG) and diacylglycerol (DAG) in both liver and tibialis anterior muscle (Fig. 4A-D). The levels of phospholipids were not affected in liver or muscle by any diet (data not shown).

*Indomethacin treatment attenuates HF/HS-induced whole-body insulin resistance.* Diet-induced accumulation of DAG and TAG in liver and muscle is associated with reduced insulin sensitivity (27-29). Thus, we examined whether inclusion of indomethacin in the diet also prevented HF/HS-induced insulin resistance. Calculation of the HOMA-IR index, indicated reduced insulin sensitivity in HF/HS fed mice, whereas mice fed HF/HS+INDO exhibited comparable levels of HOMA-IR and QUICKI to those of RD fed mice (Fig. 4E and F). Importantly, ITT demonstrated significantly reduced insulin sensitivity in HF/HS fed mice, whereas mice fed HF/HS+INDO exhibited insulin sensitivity comparable to that of mice fed RD (Fig. 4G).

*Indomethacin does not prevent hyperglycemia and impaired glucose tolerance associated with a HF/HS diet.* Despite being lean and insulin sensitive, HF/HS+INDO fed mice exhibited elevated levels of plasma glucose in the fed and fasted state compared with RD fed mice (Fig. 5A). Furthermore, HF/HS+INDO fed mice were as glucose intolerant as those fed HF/HS, indicating that HF/HS+INDO fed mice were unable to cope with the glucose challenge imposed by the GTT (Fig. 5B). Despite a reduction in glucose tolerance in mice given HF/HS+INDO, no compensatory enhancement of glucose-stimulated insulin secretion (GSIS) was observed 15 minutes after glucose injection compared to that observed in mice fed a HF/HS-diet, (Fig. 5C). To evaluate whether increased hepatic glucose output might contribute to the high plasma glucose values in HF/HS+INDO mice, a PTT was performed. Mice fed the HF/HS diet had increased blood glucose levels after a pyruvate injection compared with RD fed mice, and this was not attenuated by indomethacin (Fig. 5D). Expression of G6pc (Glucose-6-phosphatase) and Pck1 (Phosphoenolpyruvate carboxykinase 1) was significantly increased in both HF/HS and HF/HS+INDO treated mice, compared with mice fed a low fat RD (Fig. 5E and F).

*Indomethacin prevents HF/HS-induced glucose-stimulated insulin secretion.* To further investigate the reduced glucose tolerance in HF/HS+INDO fed mice, glucose tolerance and GSIS were examined in a second set of mice after 1, 2 and 3 weeks of feeding. Interestingly, the HF/HS+INDO fed mice exhibited clear signs of glucose intolerance already after one week of feeding with no alterations in GSIS as measured 15 minutes after glucose injection and no significant difference in BW (Fig. 5G&H). After 3 weeks of feeding both the HF/HS and the HF/HS+INDO fed mice were markedly glucose intolerant, but only the HF/HS fed mice exhibited a compensatory increase in GSIS reflecting the insulin resistant state of these mice (Fig. 5K&L). This indicates that indomethacin exerted an early effect on glucose intolerance that temporarily preceded changes in GSIS and increased glucose intolerance in the HF/HS fed mice. Moreover, these results suggest that indomethacin did not directly inhibit GSIS.

To establish whether indomethacin acutely affected glucose clearance and GSIS, RD fed mice were orally treated with a single dose of indomethacin. This treatment acutely impaired glucose disposal in spite of no significant impairment in GSIS (Fig. 6A-C). Neither glucose tolerance nor GSIS was affected by acute administration of indomethacin in obese, glucose intolerant HF/HS fed mice (Fig. 6D-F).

To evaluate if long term treatment with indomethacin was able to influence glucose tolerance and GSIS in the setting of a RD feeding, we fed mice RD+/−INDO, for 7 weeks. Body weight (data not shown) and WAT mass in RD+/INDO fed mice were comparable to those fed RD (Fig. 6G). In this
context indomethacin supplementation did not lead to glucose intolerance (Fig. 6H) or alterations in GSIS (Fig. 6I).

Finally, we aimed to investigate if treatment with indomethacin could reverse elevated HF/HS-induced GSIS in obese and insulin resistant mice. To increase fat mass and reduced insulin sensitivity, C57BL/6J mice were fed a HF/HS-diet for 10 weeks; then a group was switched to HF/HS+INDO-diet and another maintained on HF/HS for 8 additional weeks. Mice fed a RD were used as a reference. No reduction in BW, feed efficiency, and lean- and fat mass was observed when obese mice were fed HF/HS+INDO (Fig. 6J-M). Furthermore, we observed no effect of INDO treatment regarding glucose tolerance and GSIS in already obese animals (Fig. 6N&O).

Indomethacin treatment combined with activation of GPR40 attenuates GSIS. To corroborate the notion that mice fed HF/HS+INDO failed to compensate for a sustained hepatic glucose production, insulin levels were measured in both the fasted and fed states and β-cell mass was quantified after 8 weeks of feeding. In spite of the marked glucose intolerance, the HF/HS diet-induced hyperinsulinemia in both the fasted and fed states was not observed in HF/HS+INDO fed mice (Fig. 7A). Quantification of pancreatic β-cell mass demonstrated no reduction in β-cell mass in the HF/HS fed mice (Fig. 7B). Evaluation of insulin secretion upon an i.p. injection of glucose demonstrated that insulin secretion in mice fed the HF/HS+INDO diet was comparable to the RD fed mice, whereas it was increased in the HF/HS fed mice (Fig. 7C). Fatty acid-dependent modulation of GSIS depends on both β-cell fatty acid metabolism and signaling via GPR40/FFA1 (30-32). To examine if indomethacin cell-autonomously modulated GSIS when GPR40/FFA1 was activated, we analyzed the effect of indomethacin on GSIS in the presence and absence of a synthetic GPR40 agonist, TUG469, in mouse MIN6 cells. No effect on cell survival and growth in response to treatment with up to 10 μM indomethacin was observed (Fig. 7 D) and indomethacin alone, did not impair GSIS in MIN6 cells. However, in response to GPR40 activation in the presence of indomethacin GSIS was inhibited (Fig. 7E). Based on its structure, it was possible that indomethacin might act as an antagonist of GPR40. To investigate this possibility we employed a Bioluminescence Resonance Energy Transfer (BRET) based β-arrestin-2 interaction assay detecting the interaction between mouse GPR40 and β-arrestin-2 (32). As predicted, addition of TUG469 potently increased GPR40-β-arrestin-2 interaction. However, indomethacin did not antagonize TUG469 activation of GPR40; rather, indomethacin behaved like a low potency agonist of GPR40 (EC50 = 4.5 ± 1.3 μM) acting additive at submaximal concentrations of TUG469 (Fig. 7F). Taken together, these results indicate that indomethacin in combination of fatty acid-dependent activation of GPR40 impair GSIS, which at least in part may explain the lack of a compensatory increase in GSIS to cope with the sustained hepatic glucose output in HF/HS+INDO fed mice.

DISCUSSION

In this study we report that HF/HS diet-induced obesity, GSIS and insulin resistance, but not glucose intolerance in C57BL/6J mice was prevented by the general COX inhibitor, indomethacin. In addition, fatty acid-dependent upregulation of GSIS was perturbed in HF/HS+INDO fed mice. Together, our findings point to a complex network controlling glucose tolerance and insulin secretion regulated by an intricate relationship between HF/HS feeding and indomethacin supplementation, where the lack of a compensatory upregulation of GSIS in combination with sustained elevated hepatic gluconeogenesis resulted in a state of glucose intolerance in the otherwise lean and insulin sensitive INDO supplemented mice.

Indomethacin prevented increased adipose tissue mass and hypertrophy induced by a HF/HS diet in C57BL/6J mice. This is in striking contrast to the obesity promoting action of indomethacin together with a HF/FS diet in Sv129 mice, normally considered obesity resistant (8).

High concentration of indomethacin has previously been reported to enhance PPARγ dependent transactivation, and thereby increase adipocyte differentiation (34,35). However, the
dose of indomethacin used in the present study was low (16mg per kg diet) compared to other studies considered insufficient to raise plasma levels sufficiently high to activate PPARγ, and accordingly, expression of PPARγ and PPARγ responsive genes in adipose tissues was not significantly altered comparing indomethacin supplemented and not supplemented mice (data not shown).

The effects of PGs in lipolysis are complex. It has been shown that lipolysis is reciprocally affected by PGE2 and PGI2, and possibly also modulated by other PGs (36). Exogenous PGE2 has been shown to reduce lipolysis, while PGI2 have been shown to antagonize the anti-lipolytic effect of PGE2. Inhibition of PGH synthesis by indomethacin reduce production of both PGE2 and PGI2, and in agreement with (36), the levels of plasma glycerol and FFA in the fed state indicate that indomethacin did not seem to affect lipolysis (Fig. 2f). On the other hand, our results demonstrate that mice treated with indomethacin had a significant increase in plasma FFA after 16 hours fasting. In part, this might at least in part reflect an increased ability of fasting-induced increases in cAMP levels to promote lipolysis in the absence of inhibitory prostaglandins, and additionally, indomethacin might change the balance between lipolysis promoting and antagonizing PGs.

The observed protection against diet-induced obesity was associated with significantly reduced feed efficiency and weight gain, but surprisingly, this was not accompanied by detectable changes in O2 consumption or CO2 production. However, we cannot exclude the possibility that O2 consumption and CO2 production might be affected at a different time points during the experiment.

Insulin resistance is associated not only with obesity, but also low-grade inflammation in the adipose tissue (1,2), ectopic fat accumulation and increased DAG accumulation in both liver and skeletal muscle (37). COX-2 is necessary for the acute inflammatory response (38) and COX-2 deficiency attenuates age-dependent inflammation and infiltration of macrophages in adipose tissue (39). In the present study, inclusion of indomethacin reduced the circulating levels of 6-keto PGF1α, PGD2, and TXB2 and reduced expression of markers of macrophage infiltration and inflammation in adipose tissues. Furthermore, indomethacin supplementation abolished HF/HS-induced accumulation of TAG and DAG in liver and muscle. Reflecting their lean phenotype and suppressed expression of inflammatory markers in adipose tissue, the HF/HS+INDO fed mice remained insulin sensitive. However, they developed glucose intolerance within one week of feeding.

Similar to the obese HF/HS fed mice, mice fed HF/HS+INDO had elevated sustained expression of genes involved in hepatic gluconeogenesis, suggesting a sustained high hepatic glucose output, correlated with high fasting and fed plasma glucose. This suggests a certain degree of insulin resistance in the liver, which however was undetectable in the HF/HS+INDO fed mice using whole body ITT. A hyperinsulinemic-euglycemic clamp experiment would be needed to draw a firm conclusion on the precise contribution of hepatic glucose output to the observed hyperglycemia. Nevertheless, our PTT data convincingly demonstrated that hepatic glucose output was increased in both obese HF/HS and lean HF/HS+INDO fed mice, and the early development of glucose intolerance in the lean HF/HS+INDO fed mice indicated that these mice in spite of being insulin sensitive were unable to compensate for the increased glucose output during a GTT.

HF/HS fed mice exhibited the expected correlation between obesity and hyperinsulinemia. By contrast, plasma insulin levels in the lean HF/HS+INDO fed mice were comparable to RD mice. These differences impinge on the important question as to whether hyperinsulinemia is a compensatory action to counteract obesity-elicited inflammation and peripheral insulin resistance or whether increased plasma insulin precedes obesity development, inflammation and insulin resistance. Whereas the canonical view favors the first possibility (1,40), others and we have recently argued that a high level of insulin is a prerequisite for HF-diet-induced obesity (41-43). In keeping with this view, adipose-specific insulin receptor knockout mice are protected against diet-induced obesity (44). Thus, the leanness of the HF/HS+INDO fed mice may
reflect a similar dependency on high insulin levels to elicit the obesogenic action of the HF/HS diet. High plasma insulin levels also exert a positive feedback on β-cell mass expansion in response to HF/HS feeding, and similarly, the effect of glucose on β-cells may well depend on the increased insulin secretion. Accordingly, β-cell mass expansion and insulin hyper-secretion may eventually result in systemic insulin resistance (42,45).

The paradoxical situation of glucose intolerance in insulin sensitive mice developed only in the context of HF/HS feeding. This observation invited speculations that indomethacin in combination with a HF/HS diet perturbed the normal regulation of insulin synthesis and/or secretion from β-cells. Our finding that compared with HF/HS fed mice, mice fed HF/HS+INDO had decreased fasting and fed insulin levels and a reduced insulin secretion during a GTT suggested that indomethacin impaired HF/HS-induced GSIS.

Initially, the regulatory effect of fatty acids on GSIS was assumed to be related to fatty acid metabolism in β-cells, but now it is known that a large part of the effect depends on fatty acid activation of GPR40 (31). Using MIN6 cell as a model we demonstrated that the combined action of a selective GPR40 agonist, TUG469, and indomethacin inhibited GSIS. The augmented GSIS in HF fed C57BL/6 mice in response to i.p. glucose injection is reported to require GPR40 (32). In line with the finding that indomethacin does not influence GSIS in RD fed mice, GSIS is also unaffected in RD fed GPR40\textsuperscript{−/−} C57BL/6 mice (32). Thus, although indomethacin did not act as a GRP40 antagonist, the finding that the combined action of indomethacin and TUG469 inhibited GSIS in MIN6 cells, suggests a mechanism by which indomethacin attenuates the compensatory increased insulin secretion in HF/HS fed mice.

In conclusion, our results demonstrate that indomethacin, a commonly used COX inhibitor, prevented HF/HS-induced obesity and insulin resistance, but not glucose intolerance and increased hepatic glucose production associated with a HF/HS diet. Indomethacin did not \textit{per se} inhibit insulin secretion, but the indomethacin in combination with activation inhibited GSIS. In a situation of sustained hepatic glucose output, the inhibition of fatty acid enhancement of GSIS created a situation where pancreatic insulin secretion became insufficient to fully handle the glucose challenge of a GTT. Remaining important questions concern elucidating the precise molecular mechanisms by which indomethacin in combination with GPR40 activation inhibits GSIS and whether the effects of indomethacin and other NSAIDS can be translated into a human setting. Considering the worldwide common use of NSAIDS this question warrants further investigation.
Acknowledgments
We thank Trond Ulven for providing TUG469. We would also thank Pavel Flachs and Jan Kopecky for kindly providing the UCPI antibody. This work was supported by the EU FP7 project DIABAT (HEALTH-F2-2011-278373), the Danish Natural Science Research Council, the Novo Nordisk Foundation, the Carlsberg Foundation, the SHARE Cross Faculty PhD Initiative of University of Copenhagen and NIFES. Part of the work was carried out as a part of the research program of the Danish Obesity Research Centre (DanORC). DanORC is supported by the Danish Council for Strategic Research (Grant No: 2101 06 0005). Part of the work was also supported by the Danish Council for Strategic Research (grant 11-116196 for the FFARMED project). The F.G.H laboratory receives funding from Juvenile Diabetes Research Foundation (1-2009-337) and NIH (RO1DK090492). This study was supported in part by intramural funds from the USDA Agricultural Research Service [5306-51000-002-00D to JWN; 5306-51000-019-00D to JWN] and the National Institute of Food and Agriculture National Needs Fellowship [2008-38420-04759 to AHK].

Author contributions
E.F., K.K., I.M. designed research. E.F., U.L.A., K.R., A.H.K., T.A., K.B., D.M.K., G.W.N., T.M., B.D.H., G.M., X.Y., J.W.N., F.G.H., B.L., K.K., L.M. conducted research and analyzed data. E.F., K.K., I.M. wrote the manuscript. All authors critically revised and approved the final content of the manuscript.
REFERENCES


FIGURE LEGENDS

FIGURE 1: Effect of indomethacin supplementation on body weight gain and adipose tissue mass. Mice were fed RD, HF/HS or HF/HS+INDO for 7 weeks. The mice were killed and liver and adipose tissue depots were dissected out and weighted. (A) Body weight development during 7 weeks of feeding. (B) Mean total body weight gain after 7 weeks of feeding. (C) Mean weight of eWAT (epididymal white adipose tissue), rWAT (retroperitoneal white adipose tissue), and iWAT (inguinal white adipose tissue). (D) Mean liver weight. (E) Mean weight of iBAT (interscapular brown adipose tissue). (F) Total energy intake calculated from the amount of food eaten during the experiment. (G) Energy efficiency calculated as weight gain relative to Megajoule (kJ). (H) Feces were collected for 48 hours and the fat content measured to estimate percentage fat absorption. (I) Total percentage weight loss after 12 hours starvation in mice treated with the respective diets. All results are presented as mean ± SEM (n=8-9). Statistical significances are denoted with stars; * P≤0.05, ** P≤0.01, *** P≤0.001.

FIGURE 2: The effect of indomethacin on metabolic performance, expression of markers of brown and brown-like adipocytes, and plasma levels of glycerol, NEFA, alanine aminotransferase (ALT), and aspartate transaminase (AST) after 7 weeks of feeding. Mice fed RD, HF/HS and HF/HS+INDO were placed in open circuit chamber for 24 hours for measurements of O₂ consumption and CO₂ production. (A and B) O₂ uptake and production CO₂ expressed as ml/h/kg. (C) Calculation of respiratory exchange ratio (RER). (D-F) mRNA levels of markers of brown and brown-like adipocytes in iBAT, eWAT and iWAT. Ucp1 (Uncoupling protein 1), Dio2 (Deiodinase, iodothyronine, type II), Pparc1a ( Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha). (G) Immunohistochemistry (IHC) staining with UCP1-antibody for detection of multilocular cells in representative sections from eWAT and iWAT. (I) Plasma levels of ALT measured in the fed state and AST measured in the fasted state (12h). (I) Plasma glycerol levels in fed and fasted mice. (J) Plasma levels of NEFA in the fed and the fasted state. The results are presented as mean ± SEM (n=8-9). Statistical significances are denoted with stars; * P≤0.05, ** P≤0.01, *** P≤0.001.

FIGURE 3: Effects of indomethacin supplementation on adipocyte morphology and inflammation. (A) Morphology of eWAT and iWAT from mice fed RD, HF/HS and HF/HS+INDO for 7 weeks (n=3). The tissues were stained with hematoxylin-eosin. Micrographs from one representative mouse in each group is shown. (B-I) Quantitative real-time RT-PCR analysis of markers of macrophage infiltration and inflammation in eWAT (B-E) and iWAT. Cd68 (Cluster of differentiation 68), Emr1 (Egf-like module containing, mucin-like, hormone receptor-like 1), Serpine1 (Serpin peptidase inhibitor, clade E, member 1), Ccl2 (Chemokine ligand 2) (F-I). (J) Immunohistochemistry (IHC) staining with F4/80-antibody for detection of macrophages and Crown-like structures (CLS) in representative sections from eWAT and iWAT. The results are presented as mean ± SEM (n=8-9). Statistical significances are denoted with stars; ** P≤0.01, *** P≤0.001.

FIGURE 4: Effects of indomethacin supplementation on lipid accumulation in liver and muscle and insulin sensitivity. Quantitative analyses of lipids in the liver and muscle of mice fed RD, HF/HS and IIF/IIS+INDO for 7 weeks were performed (n=8-9). (A) Triacylglycerol (TAG) and (B) diacylglycerol (DAG) in liver. (C) TAG and (D) DAG in tibialis anterior muscle. (E) HOMA-IR calculated from fasting plasma (12h) levels of insulin and glucose. (F) QUICKI (G) ITT after 6 weeks on the respective diets. Blood glucose from RD fed mice were significantly different from mice given a HF/HS diet at timepoint 15, 30, 45 and 60 after injection, but is not shown in figure. All results are presented as mean ± SEM (n=8-9). Statistical significances are denoted with stars; * P≤0.05, ** P≤0.01. *** P≤0.001.

FIGURE 5: Effects of indomethacin supplementation on glucose tolerance, insulin sensitivity, hepatic glucose production and glucose-stimulated insulin secretion. (A) Plasma blood glucose levels in fed and 12 hours fasted animals after 7 weeks of feeding. (B) Intraperitoneal glucose tolerance test (2g/kg) performed on mice fasted for 6 hours. (C) GSIS during GTT after 7 weeks treatment with the respective diets. (D) PTT after 6 weeks of feeding with a RD, IIF/HS and the
HF/HS+INDO diet. (D-E) mRNA levels of G6pc (Glucose-6-phosphatase) and Pck1 (Phosphoenolpyruvate carboxykinase 1) in liver in the fed state. The results are presented as mean ± SEM (n=8-9). (G-H) GTT and GSIS after 1 week on the respective diets. (I-J) GTT and GSIS after 2 weeks. (K-L) GTT and GSIS after 3 weeks. Statistical significances are denoted with stars; * P≤0.05, ** P≤0.01, *** P≤0.00

FIGURE 6: Effects of acute COX-inhibition with indomethacin, indomethacin combined in a balanced RD diet and indomethacin supplementation to already obese animals. (A-C) Acute effects of indomethacin on GTT and GSIS in C57BL/6J mice given an RD diet for 1 week. The mice were given indomethacin (2.5 mg/kg-BW) orally 1 hour before a glucose tolerance test during which GSIS was also evaluated. (D-F) Acute effects of indomethacin on glucose tolerance and GSIS in mice fed a HF/HS diet for 10 weeks. (G) Weight of eWAT, rWAT and iWAT in mice fed RD and RD+INDO for 7 weeks. (H-I) GTT and GSIS after 6 weeks of feeding with RD supplemented with indomethacin. (J-O) Mice were fed RD or a HF/HS diet for 10 weeks, and then continued on either a HF/HS diet with or without indomethacin supplementation or the RD diet for additional 8 weeks. (J) BW, (K) feed efficiency, (L) lean body mass and (M) fat mass is shown for 6 weeks after changing the diet. (N-O) GTT and GSIS on the mice shown in J-M. The results are presented as mean ± SEM (n=8-9). Statistical significances are denoted with stars; * P≤0.05, ** P≤0.01, *** P≤0.00

FIGURE 7: Effects of indomethacin supplementation on glucose-stimulated first phase insulin secretion in C57BL/6J mice, and TUG469 stimulated insulin secretion in MIN6 cells. (A) Plasma insulin levels in fed and 12 hours fasted animals after 8 weeks of feeding. (B) Pancreatic islet and section sizes were analyzed, and islet size as a percentage of total pancreas size was calculated (n=5). (C) First phase insulin secretion and glucose-stimulated insulin secretion measured after 3 hours fasting. (D) MIN6 cells treated with indomethacin at 0.1, 1 or 10μM. (E) MIN6 cells treated with vehicle, indomethacin (1μM), TUG469 or TUG469+INDO. After 1 hour incubation, insulin release was measured. (F) Effects of TUG469 and Indomethacin on β-arrestin-2 recruitment to mouse GPR40. BRET signals normalized to the maximal TUG469 response obtained following treatment with varying concentrations of TUG469 (blue) or INDO (red) on their own, or to varying concentrations of INDO in the presence of 100 nM TUG469 (green). The results are presented as mean ± SEM (n=8-9). Statistical significances are denoted with stars; * P≤0.05, ** P≤0.01, *** P≤0.00
TABLE 1: Average plasma concentrations of oxylipin metabolites (nM). The levels of plasma oxylipids were determined by UPLC-MS/MS. Results are presented as mean ± SD (n=6). P-values were calculated by 2-tailed t-test. Statistical significances are denoted with stars; * P≤0.05, ** P≤0.01.

<table>
<thead>
<tr>
<th>Analyte</th>
<th>Parent</th>
<th>Class</th>
<th>HF/HS</th>
<th>HF/HS + INDO</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGD2</td>
<td>AA</td>
<td>Prostaglandin</td>
<td>0.376 ± 0.140</td>
<td>0.108 ± 0.086</td>
<td>**</td>
</tr>
<tr>
<td>PGF2a</td>
<td>AA</td>
<td>Prostaglandin</td>
<td>0.184 ± 0.0782</td>
<td>0.0667 ± 0.081</td>
<td>*</td>
</tr>
<tr>
<td>6-keto PGF1a</td>
<td>AA</td>
<td>Prostaglandin</td>
<td>0.537 ± 0.208</td>
<td>0.226 ± 0.1</td>
<td>**</td>
</tr>
<tr>
<td>TXB2</td>
<td>AA</td>
<td>Thromboxane</td>
<td>0.229 ± 0.195</td>
<td>n/d</td>
<td>*</td>
</tr>
<tr>
<td>12-HETE</td>
<td>AA</td>
<td>Alcohol</td>
<td>115 ± 75.4</td>
<td>117 ± 67</td>
<td>ns</td>
</tr>
<tr>
<td>11-HETE</td>
<td>AA</td>
<td>Alcohol</td>
<td>1.85 ± 1.82</td>
<td>2.88 ± 4.4</td>
<td>ns</td>
</tr>
<tr>
<td>9-HETE</td>
<td>AA</td>
<td>Alcohol</td>
<td>3.66 ± 3.26</td>
<td>5.12 ± 7.5</td>
<td>ns</td>
</tr>
<tr>
<td>8-HETE</td>
<td>AA</td>
<td>Alcohol</td>
<td>3.71 ± 3.03</td>
<td>5.53 ± 4.2</td>
<td>ns</td>
</tr>
<tr>
<td>5-HETE</td>
<td>AA</td>
<td>Alcohol</td>
<td>6.32 ± 7.26</td>
<td>6.88 ± 7.3</td>
<td>ns</td>
</tr>
<tr>
<td>15-HEPE</td>
<td>EPA</td>
<td>Alcohol</td>
<td>0.190 ± 0.138</td>
<td>0.204 ± 0.23</td>
<td>ns</td>
</tr>
<tr>
<td>12-HEPE</td>
<td>EPA</td>
<td>Alcohol</td>
<td>1.69 ± 1.59</td>
<td>1.24 ± 0.78</td>
<td>ns</td>
</tr>
<tr>
<td>15-HETrE</td>
<td>GLA</td>
<td>Alcohol</td>
<td>1.15 ± 1.04</td>
<td>1.94 ± 3</td>
<td>ns</td>
</tr>
<tr>
<td>13-HODE</td>
<td>LA</td>
<td>Alcohol</td>
<td>131 ± 51.0</td>
<td>177 ± 83</td>
<td>ns</td>
</tr>
<tr>
<td>9-HODE</td>
<td>LA</td>
<td>Alcohol</td>
<td>28.0 ± 12.9</td>
<td>29.2 ± 16</td>
<td>ns</td>
</tr>
<tr>
<td>9-HOTE</td>
<td>ALA</td>
<td>Alcohol</td>
<td>1.93 ± 0.258</td>
<td>1.8 ± 0.63</td>
<td>ns</td>
</tr>
<tr>
<td>13-HOTE</td>
<td>ALA</td>
<td>Alcohol</td>
<td>1.71 ± 0.281</td>
<td>1.52 ± 0.84</td>
<td>ns</td>
</tr>
<tr>
<td>15-KETE</td>
<td>AA</td>
<td>Ketone</td>
<td>4.32 ± 2.29</td>
<td>2.54 ± 0.76</td>
<td>ns</td>
</tr>
<tr>
<td>12-KETE</td>
<td>AA</td>
<td>Ketone</td>
<td>4.42 ± 2.32</td>
<td>2.72 ± 0.76</td>
<td>ns</td>
</tr>
<tr>
<td>5-KETE</td>
<td>AA</td>
<td>Ketone</td>
<td>2.97 ± 1.74</td>
<td>2.15 ± 1.6</td>
<td>ns</td>
</tr>
<tr>
<td>13-KODE</td>
<td>LA</td>
<td>Ketone</td>
<td>96.3 ± 80.1</td>
<td>95.5 ± 72</td>
<td>ns</td>
</tr>
<tr>
<td>12(13)-EpOME</td>
<td>LA</td>
<td>Epoxide</td>
<td>32.7 ± 9.41</td>
<td>29.9 ± 20</td>
<td>ns</td>
</tr>
<tr>
<td>15(16)-EpODE</td>
<td>ALA</td>
<td>Epoxide</td>
<td>2.16 ± 0.623</td>
<td>2.05 ± 1.2</td>
<td>ns</td>
</tr>
<tr>
<td>9(10)-EpODE</td>
<td>ALA</td>
<td>Epoxide</td>
<td>2.24 ± 0.847</td>
<td>2.66 ± 1.4</td>
<td>ns</td>
</tr>
<tr>
<td>14,15-DIHETrE</td>
<td>AA</td>
<td>Dial</td>
<td>1.49 ± 0.602</td>
<td>0.929 ± 0.13</td>
<td>ns</td>
</tr>
<tr>
<td>5,6-DIHETrE</td>
<td>AA</td>
<td>Dial</td>
<td>0.459 ± 0.117</td>
<td>0.412 ± 0.15</td>
<td>ns</td>
</tr>
<tr>
<td>17,18-DIHETE</td>
<td>EPA</td>
<td>Dial</td>
<td>2.67 ± 1.36</td>
<td>2.08 ± 0.86</td>
<td>ns</td>
</tr>
<tr>
<td>14,15-DIHETE</td>
<td>EPA</td>
<td>Dial</td>
<td>0.330 ± 0.108</td>
<td>0.213 ± 0.17</td>
<td>ns</td>
</tr>
<tr>
<td>19,20-DiHDP A</td>
<td>DHA</td>
<td>Dial</td>
<td>1.76 ± 0.731</td>
<td>1.36 ± 0.24</td>
<td>ns</td>
</tr>
<tr>
<td>9,10-DIHOME</td>
<td>LA</td>
<td>Dial</td>
<td>48.8 ± 19.2</td>
<td>51.1 ± 15</td>
<td>ns</td>
</tr>
<tr>
<td>9,10-DIHOME</td>
<td>ALA</td>
<td>Dial</td>
<td>0.189 ± 0.235</td>
<td>0.174 ± 0.22</td>
<td>ns</td>
</tr>
<tr>
<td>9,12,13-TriHOME</td>
<td>LA</td>
<td>Triol</td>
<td>3.35 ± 1.55</td>
<td>2.48 ± 1.3</td>
<td>ns</td>
</tr>
<tr>
<td>9,10,13-TriHOME</td>
<td>LA</td>
<td>Triol</td>
<td>1.48 ± 1.22</td>
<td>0.876 ± 0.68</td>
<td>ns</td>
</tr>
</tbody>
</table>
Cyclooxygenase inhibition and regulation of glucose homeostasis
Cyclooxygenase inhibition and regulation of glucose homeostasis

Fig. 3

A  
RD    HF/HS    HF/HS + INDO

eWAT

IWAT

B  
Cd68

C  
Emr1

D  
Serpine1

E  
Ccl2

F  
Cd68

G  
Emr1

H  
Serpine1

I  
Ccl2

J  
RD    HF/HS    HF/HS + INDO

eWAT

IWAT
Fig. 4

A

<table>
<thead>
<tr>
<th></th>
<th>RD</th>
<th>HF/HFS</th>
<th>HF/HFS + INDO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transfer (mg/h)</td>
<td>60</td>
<td>50</td>
<td>40</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>0</td>
<td>0.5</td>
<td>0.4</td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th></th>
<th>RD</th>
<th>HF/HFS</th>
<th>HF/HFS + INDO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transfer (mg/h)</td>
<td>60</td>
<td>50</td>
<td>40</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>0</td>
<td>0.5</td>
<td>0.4</td>
</tr>
</tbody>
</table>

C

<table>
<thead>
<tr>
<th></th>
<th>RD</th>
<th>HF/HFS</th>
<th>HF/HFS + INDO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transfer (mg/h)</td>
<td>15</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>0</td>
<td>0.5</td>
<td>0.4</td>
</tr>
</tbody>
</table>

D

<table>
<thead>
<tr>
<th></th>
<th>RD</th>
<th>HF/HFS</th>
<th>HF/HFS + INDO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transfer (mg/h)</td>
<td>15</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>0</td>
<td>0.5</td>
<td>0.4</td>
</tr>
</tbody>
</table>

E

<table>
<thead>
<tr>
<th></th>
<th>RD</th>
<th>HF/HFS</th>
<th>HF/HFS + INDO</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOME-1 (mol/L)</td>
<td>0.5</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>HOME-2 (mol/L)</td>
<td>0</td>
<td>0.5</td>
<td>0.4</td>
</tr>
</tbody>
</table>

F

<table>
<thead>
<tr>
<th></th>
<th>RD</th>
<th>HF/HFS</th>
<th>HF/HFS + INDO</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOME-1 (mol/L)</td>
<td>0.5</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>HOME-2 (mol/L)</td>
<td>0</td>
<td>0.5</td>
<td>0.4</td>
</tr>
</tbody>
</table>

G

<table>
<thead>
<tr>
<th></th>
<th>RD</th>
<th>HF/HFS</th>
<th>HF/HFS + INDO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood glucose (%)</td>
<td>100</td>
<td>80</td>
<td>60</td>
</tr>
<tr>
<td>Insulin (mU/L)</td>
<td>0</td>
<td>0.5</td>
<td>0.4</td>
</tr>
</tbody>
</table>

Time (min) | 0  | 15 | 30 | 45 | 60 | 80

AUC-ITT (%) x 60 min | 0  | 0  | 0  | 0  | 0  | 0
Fig. 6

A. Initial blood glucose (mM) vs. Time (min)

B. Blood glucose (mM) vs. Time (min)

C. AUC GTT (mg/dL x 60 min)

D. Initial blood glucose (mM) vs. Time (min)

E. Blood glucose (mM) vs. Time (min)

F. AUC GTT (mg/dL x 60 min)

G. WAT weight (g)

H. Blood glucose (mM) vs. Time (min)

I. Plasma insulin (U/L)

J. Body weight (g) vs. Weeks

K. Feed efficiency vs. Body weight

L. Lean mass (g)

M. Fat mass (g)

N. Blood glucose (mM) vs. Time (min)

O. Plasma insulin (U/L)
Cyclooxygenase inhibition and regulation of glucose homeostasis

Fig. 7

A

B

C

D

E

F

Plasma insulin (ng/mL)

Fed
Fasted

Insulin (ng/mL)

2.8 mM
20 mM

β-Arrestin-2 BRET

Log[Ligand]